212 related articles for article (PubMed ID: 17034582)
21. Heterogeneity of Acetylcholine Receptor Autoantibody-Mediated Complement Activity in Patients With Myasthenia Gravis.
Obaid AH; Zografou C; Vadysirisack DD; Munro-Sheldon B; Fichtner ML; Roy B; Philbrick WM; Bennett JL; Nowak RJ; O'Connor KC
Neurol Neuroimmunol Neuroinflamm; 2022 Jul; 9(4):. PubMed ID: 35473886
[TBL] [Abstract][Full Text] [Related]
22. Complement regulators in extraocular muscle and experimental autoimmune myasthenia gravis.
Kaminski HJ; Li Z; Richmonds C; Lin F; Medof ME
Exp Neurol; 2004 Oct; 189(2):333-42. PubMed ID: 15380483
[TBL] [Abstract][Full Text] [Related]
23. The susceptibility to experimental myasthenia gravis of STAT6-/- and STAT4-/- BALB/c mice suggests a pathogenic role of Th1 cells.
Wang W; Ostlie NS; Conti-Fine BM; Milani M
J Immunol; 2004 Jan; 172(1):97-103. PubMed ID: 14688314
[TBL] [Abstract][Full Text] [Related]
24. Acetylcholine receptors loss and postsynaptic damage in MuSK antibody-positive myasthenia gravis.
Shiraishi H; Motomura M; Yoshimura T; Fukudome T; Fukuda T; Nakao Y; Tsujihata M; Vincent A; Eguchi K
Ann Neurol; 2005 Feb; 57(2):289-93. PubMed ID: 15668981
[TBL] [Abstract][Full Text] [Related]
25. C57BL/6 mice genetically deficient in IL-12/IL-23 and IFN-gamma are susceptible to experimental autoimmune myasthenia gravis, suggesting a pathogenic role of non-Th1 cells.
Wang W; Milani M; Ostlie N; Okita D; Agarwal RK; Caspi RR; Conti-Fine BM
J Immunol; 2007 Jun; 178(11):7072-80. PubMed ID: 17513756
[TBL] [Abstract][Full Text] [Related]
26. Predictive value of serum anti-C1q antibody levels in experimental autoimmune myasthenia gravis.
Tüzün E; Saini SS; Ghosh S; Rowin J; Meriggioli MN; Christadoss P
Neuromuscul Disord; 2006 Feb; 16(2):137-43. PubMed ID: 16427283
[TBL] [Abstract][Full Text] [Related]
27. Acetylcholine receptor antibody-mediated animal models of myasthenia gravis and the role of complement.
Kusner LL; Sengupta M; Kaminski HJ
Ann N Y Acad Sci; 2018 Feb; 1413(1):136-142. PubMed ID: 29356015
[TBL] [Abstract][Full Text] [Related]
28. Novel complement inhibitor limits severity of experimentally myasthenia gravis.
Soltys J; Kusner LL; Young A; Richmonds C; Hatala D; Gong B; Shanmugavel V; Kaminski HJ
Ann Neurol; 2009 Jan; 65(1):67-75. PubMed ID: 19194881
[TBL] [Abstract][Full Text] [Related]
29. Crry, but not CD59 and DAF, is indispensable for murine erythrocyte protection in vivo from spontaneous complement attack.
Miwa T; Zhou L; Hilliard B; Molina H; Song WC
Blood; 2002 May; 99(10):3707-16. PubMed ID: 11986227
[TBL] [Abstract][Full Text] [Related]
30. A new mouse model of autoimmune ocular myasthenia gravis.
Yang H; Wu B; Tüzün E; Saini SS; Li J; Allman W; Higgs S; Xiao TL; Christadoss P
Invest Ophthalmol Vis Sci; 2007 Nov; 48(11):5101-11. PubMed ID: 17962462
[TBL] [Abstract][Full Text] [Related]
31. Complement C2 siRNA mediated therapy of myasthenia gravis in mice.
Huda R; Tüzün E; Christadoss P
J Autoimmun; 2013 May; 42():94-104. PubMed ID: 23410585
[TBL] [Abstract][Full Text] [Related]
32. Experimental autoimmune myasthenia gravis in mice expressing human immunoglobulin loci.
Stassen MH; Meng F; Melgert E; Machiels BM; Im SH; Fuchs S; Gerritsen AF; van Dijk MA; van de Winkel JG; De Baets MH
J Neuroimmunol; 2003 Feb; 135(1-2):56-61. PubMed ID: 12576224
[TBL] [Abstract][Full Text] [Related]
33. Pathological mechanisms in experimental autoimmune myasthenia gravis. II. Passive transfer of experimental autoimmune myasthenia gravis in rats with anti-acetylcholine recepotr antibodies.
Lindstrom JM; Engel AG; Seybold ME; Lennon VA; Lambert EH
J Exp Med; 1976 Sep; 144(3):739-53. PubMed ID: 182897
[TBL] [Abstract][Full Text] [Related]
34. Myasthenia gravis as a prototype autoimmune receptor disease.
Hoedemaekers AC; van Breda Vriesman PJ; De Baets MH
Immunol Res; 1997; 16(4):341-54. PubMed ID: 9439759
[TBL] [Abstract][Full Text] [Related]
35. Myasthenia gravis without acetylcholine-receptor antibody: a distinct disease entity.
Mossman S; Vincent A; Newsom-Davis J
Lancet; 1986 Jan; 1(8473):116-9. PubMed ID: 2417076
[TBL] [Abstract][Full Text] [Related]
36. Experimental autoimmune myasthenia gravis in the mouse.
Wu B; Goluszko E; Huda R; Tüzün E; Christadoss P
Curr Protoc Immunol; 2011 Nov; Chapter 15():Unit 15.23. PubMed ID: 22048803
[TBL] [Abstract][Full Text] [Related]
37. Decreased expression of miR-29 family associated with autoimmune myasthenia gravis.
Cron MA; Payet CA; Fayet OM; Maillard S; Truffault F; Fadel E; Guihaire J; Berrih-Aknin S; Liston A; Le Panse R
J Neuroinflammation; 2020 Oct; 17(1):294. PubMed ID: 33032631
[TBL] [Abstract][Full Text] [Related]
38. Immune complexes (IgG and C3) at the motor end-plate in myasthenia gravis: ultrastructural and light microscopic localization and electrophysiologic correlations.
Engel AG; Lambert EH; Howard FM
Mayo Clin Proc; 1977 May; 52(5):267-80. PubMed ID: 870771
[TBL] [Abstract][Full Text] [Related]
39. Complement activation at the motor end-plates in amyotrophic lateral sclerosis.
Bahia El Idrissi N; Bosch S; Ramaglia V; Aronica E; Baas F; Troost D
J Neuroinflammation; 2016 Apr; 13(1):72. PubMed ID: 27056040
[TBL] [Abstract][Full Text] [Related]
40. Acetylcholine receptor-induced experimental myasthenia gravis: what have we learned from animal models after three decades?
Baggi F; Antozzi C; Toscani C; Cordiglieri C
Arch Immunol Ther Exp (Warsz); 2012 Feb; 60(1):19-30. PubMed ID: 22159475
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
